eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EFTR vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ALVO, ACABW, ACABU, BFRIW, and BTMDWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Alvotech (ALVO), Atlantic Coastal Acquisition Corp. II (ACABW), Atlantic Coastal Acquisition Corp. II (ACABU), Biofrontera (BFRIW), and biote (BTMDW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Alvotech Atlantic Coastal Acquisition Corp. II Atlantic Coastal Acquisition Corp. II Biofrontera biote 180 Life Sciences (NASDAQ:ATNFW) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts rate ATNFW or EFTR? eFFECTOR Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 11,999,900.00%. Given eFFECTOR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe eFFECTOR Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00eFFECTOR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ATNFW or EFTR more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A eFFECTOR Therapeutics N/A N/A -146.23% Does the MarketBeat Community prefer ATNFW or EFTR? eFFECTOR Therapeutics received 23 more outperform votes than 180 Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AeFFECTOR TherapeuticsOutperform Votes2379.31% Underperform Votes620.69% Do institutionals and insiders believe in ATNFW or EFTR? 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, ATNFW or EFTR? 180 Life Sciences has higher earnings, but lower revenue than eFFECTOR Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AeFFECTOR Therapeutics$3.55M0.00-$35.81M-$13.080.00 Does the media favor ATNFW or EFTR? In the previous week, 180 Life Sciences' average media sentiment score of 0.00 beat eFFECTOR Therapeutics' score of -1.17 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Neutral eFFECTOR Therapeutics Negative SummaryeFFECTOR Therapeutics beats 180 Life Sciences on 7 of the 9 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1,000.00$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.07%P/E Ratio0.0010.78135.4117.82Price / Sales0.00243.701,160.9774.55Price / CashN/A22.1633.5332.53Price / Book0.005.474.674.68Net Income-$35.81M$153.61M$119.07M$226.08M7 Day PerformanceN/A-2.00%-1.83%-1.04%1 Month PerformanceN/A-7.46%-3.60%1.04%1 Year PerformanceN/A31.82%31.66%26.28% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR Therapeutics1.2787 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010Negative NewsATNFW180 Life SciencesN/A$0.01flatN/A-25.0%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.04-20.6%N/A-71.9%$0.00N/A0.002AIMDWAinosN/A$0.03flatN/AN/A$0.00$40,633.000.0040ALVOWAlvotechN/A$3.10-7.7%N/A+105.3%$0.00$306.77M0.004ALVOAlvotech2.2902 of 5 stars$12.36-0.5%$18.00+45.6%+35.9%$0.00$93.38M-6.711,026ACABWAtlantic Coastal Acquisition Corp. IIN/A$0.08flatN/A+77.4%$0.00N/A0.004ACABUAtlantic Coastal Acquisition Corp. IIN/A$8.05-26.8%N/A-23.6%$0.00N/A0.004Gap DownBFRIWBiofronteraN/A$0.05flatN/A+179.9%$0.00$35.24M0.0070BTMDWbioteN/A$0.50flatN/AN/A$0.00$187.23M0.00N/A Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EFTR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
